Merck bags options on Evaxion's AI-designed vaccines, offering small upfront and big back end

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects against gonorrhea and an undisclosed infectious agent.